EMA/364197/2024

European Medicines Agency decision

P/0296/2024

of 16 August 2024

on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine / meloxicam, (EMEA-002246-PIP01-17-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0296/2024

of 16 August 2024

on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine / meloxicam, (EMEA-002246-PIP01-17-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0013/2019 issued on 3 January 2019, the decision P/0088/2020 issued on 18 March 2020, the decision P/0182/2021 issued on 10 May 2021 and the decision P/0160/2023 issued on 12 May 2023,

Having regard to the application submitted by Heron Therapeutics B.V. on 22 March 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 June 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for bupivacaine / meloxicam, prolonged-release wound solution, intralesional use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Heron Therapeutics B.V., Herengracht 500, 1017 CB – Amsterdam, The Netherlands.

EMA/PDCO/144765/2024 Corr[1]
Amsterdam, 28 June 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002246-PIP01-17-M05

Scope of the application

Active substance(s):

Bupivacaine / meloxicam

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of acute postoperative pain

Pharmaceutical form(s):

Prolonged-release wound solution

Route(s) of administration:

Intralesional use

Name/corporate name of the PIP applicant:

Heron Therapeutics B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Heron Therapeutics B.V. submitted to the European Medicines Agency on 22 March 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0013/2019 issued on 3 January 2019, the decision P/0088/2020 issued on 18 March 2020, the decision P/0182/2021 issued on 10 May 2021 and the decision P/0160/2023 issued on 12 May 2023.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

[1] 6 August 2024

The procedure started on 29 April 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of acute postoperative pain

2.1.1. Indication(s) targeted by the PIP

Treatment of acute postoperative pain

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Prolonged-release wound solution

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable.
Non-clinical studies	**Study 1** Definitive juvenile toxicity study to assess the potential general toxicity of meloxicam including the development of kidney, liver, lung, and testes in neonatal animals (HTX-011-nonclinical-2). **Study 2** Definitive juvenile toxicity study to assess the potential toxicity of the dimethyl sulfoxide excipient on the CNS via histopathology, long-term functional and cognitive assessments and ophthalmic examinations (HTX-011-nonclinical-1).
Clinical studies	**Study 3** Randomised, double-blind, active controlled, multicentre study to evaluate the PK, PD, and safety and tolerability of a single-dose administration into the surgical site of HTX-011 compared with bupivacaine HCl 0.25% (without epinephrine) in adolescents and children from 3 to less than 18 years of age undergoing soft tissue surgical procedures (HTX-011-clinical-1; HTX-011-225).

	Study 4 Study deleted during modification EMEA-002246-PIP01-17-M05
Extrapolation, modelling and simulation studies	**Study 5** Step-up (physiologically based) pharmacokinetic (PBPK) Modelling and Simulation to support dose selection for adolescents (12 to less than 18 years of age) (HTX-011-PBPK-1). **Study 6** Study deleted during modification EMEA-002246-PIP01-17-M05 **Study 7** Study deleted during modification EMEA-002246-PIP01-17-M05 **Study 8** Study deleted during modification EMEA-002246-PIP01-17-M05 **Study 9** Study deleted during modification EMEA-002246-PIP01-17-M05 **Study 10** Study deleted during modification EMEA-002246-PIP01-17-M05 **Study 11** Study deleted during modification EMEA-002246-PIP01-17-M05 **Study 12** Study deleted during modification EMEA-002246-PIP01-17-M05
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community